Company intelligence / Profile preview

Kailos Genetics

Huntsville, Alabama, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Kailos Genetics operates a CLIA-certified, CAP-accredited genomics lab offering advanced next-generation sequencing-based genetic testing services for hereditary cancer risk, pharmacogenetics, and other precision medicine applications. The company’s technologies are integrated in both clinical and consumer-facing health solutions, now as part of healthOme’s offering after its 2023 acquisition.

Therapeutic areas: OncologyOther
Modalities: Genetic testNext-generation sequencing assay
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Kailos Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kailos Genetics.

Explore the full profile